Researchers at the University of Notre Dame have discovered a way to make influenza visible to the naked eye, according to a new study in the Journal of the American Chemical Society.
By engineering dye molecules to target a specific enzyme of the virus, the team was able to develop a test kit that emitted fluorescent light when illuminated with a hand-held lamp or blue laser pointer.
Scientists used test samples that mimicked that of an infected patient, and spiked the samples with the enzyme, called neuraminidase, which had been purified from flu virus. The samples emit red fluorescent light as a positive indication of the influenza virus. Blue fluorescent light signals a negative result. The same process also allowed scientists to determine which of two approved antiviral drugs would be a better treatment option for the individual patient.
While still a prototype, researchers believe that with optimization the diagnostic could be developed to be used in point of care clinics or the home environment for a rapid, easy to interpret test for the presence of influenza.
“Viral cultures are the gold standard for diagnosis of influenza but take several days to develop. By targeting an enzyme inherent to the virus and identifying its presence in a sample, we can make a rapid determination of the influenza in a patient for an efficient and immediate diagnostic that would improve patient treatment and reduce overuse of antivirals,” said Bradley Smith, Emil T. Hofman Professor of Chemistry and Biochemistry in the Department of Chemistry and Biochemistry, director of the Notre Dame Integrated Imaging Facility and co-author of the study.
Smith and his team created a new method to detect neuraminidase, which is located on the surface of the virus. Researchers began by designing a dye molecule to emit red fluorescent light when it interacts with the neuraminidase. Following validation of enzyme recognition, researchers then tested the dye with two antiviral drugs used to treat influenza — Zanamivir, also known as Relenza, and Oseltamivir, known widely as Tamiflu. The antivirals are neuraminidase inhibitors. Samples containing dye and neuraminidase were combined with each of the antivirals and illuminated. Red fluorescence indicated the enzyme was still active, meaning the antiviral failed to inhibit the virus in that patient. Blue light indicated the enzyme had been blocked, presenting an effective treatment option.
The study, which received funding from the National Science Foundation and Notre Dame’s research initiative, Advanced Diagnostics and Therapeutics, focused specifically on fluorescence detection of the virus and efficacy of the two inhibitors. Smith’s team hopes to build upon these results in the future.
The Latest on: Influenza diagnostic
- Influenza Diagnostics Market - Sophisticated Demand 2025 | Luminex Corporation, Thermo Fisher Scientific, Alere Inc. on June 10, 2019 at 3:09 am
Types of influenza include pandemic, avian, seasonal, and swine (variant) flu. Numerous tests aid in the diagnosis and treatment of influenza. Some of these available diagnostic tests are serology, ... […]
- Smartphone flu test could be coming to Aussie households on June 8, 2019 at 7:00 am
A BAN on home flu tests could be lifted to let Australians use a world-first smartphone diagnosis invented by a Brisbane doctor. Emergency medic Sean Parsons has won the backing of global health giant ... […]
- As Nipah returns, can other threats be far behind this monsoon season? on June 7, 2019 at 9:58 am
In fact, basic public health protocols in diagnosis, treatment and hygiene can tackle Nipah and other illnesses that the monsoon brings with it. Influenza virus activity is already on a rise and is ... […]
- Co-subsistence of avian influenza virus subtypes of low and high pathogenicity in Bangladesh: Challenges for diagnosis, risk assessment and control on June 5, 2019 at 2:07 am
Endemic co-circulation of potentially zoonotic avian influenza viruses (AIV) of subtypes H5N1 and H9N2 (G1 lineage) in poultry in Bangladesh accelerated diversifying evolution. Two clinical samples ... […]
- Singapore biomedical firm to test new rapid diagnostic kit for flu on June 5, 2019 at 1:04 am
HONG KONG - A Singapore company believes it has moved a step nearer eliminating deaths due to complications from influenza by developing an on-the-spot test which it claims is more accurate than those ... […]
via Google News and Bing News